Skip to content

Safety and Efficacy of Moxidex Otic

Safety and Efficacy Evaluation of Topical Moxidex Otic Solution in the Treatment of Acute Otitis Media With Otorrhea in Tympanostomy Tubes

Status
Terminated
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01071902
Enrollment
400
Registered
2010-02-19
Start date
2010-02-28
Completion date
2011-10-31
Last updated
2012-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Otitis Media

Keywords

ear tubes, ear drainage, ear infection, ear drops, acute otitis media

Brief summary

The purpose of this study is to determine if Moxidex otic solution is safe and effective in treating middle ear infections in patients with ear tubes.

Interventions

OTHERVehicle

4 drops into the infected ear(s) twice daily (morning and evening) for 7 days

4 drops into the infected ear(s) twice daily (morning and evening) for 7 days

4 drops into the infected ear(s) twice daily (morning and evening) for 7 days

Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children

Sponsors

Alcon Research
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
6 Months to 12 Years
Healthy volunteers
No

Inclusion criteria

* 6 months to 12 years of age * Ear tubes in one or both ears * Ear drainage visible by parent/guardian * Ear drainage less than 21 days * Other protocol-defined inclusion criteria may apply

Exclusion criteria

* Patients not otorrhea-free for 7 or less following tympanostomy tube surgery * Ear tube with antimicrobial activity; ear tube longer than 2.5mm * Non-tube otorrhea * No otic surgery other than tube placement in the last year * No menarchial females; no diabetic patients * No patients with any disease or condition that would negatively affect the conduct of the study * No patients taking any other systemic antimicrobial therapy during the study * Patient must meet certain medication washouts to be eligible * Analgesic use (other than acetaminophen) is not allowed * Patients may not be predisposed to neurosensory hearing loss * Other protocol-defined

Design outcomes

Primary

MeasureTime frame
Clinical Cure at End of TreatmentDay 8

Secondary

MeasureTime frame
Time to Cessation of OtorrheaFrom First Dose
Microbiological Success at End of TreatmentDay 8

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026